Standard IOLs with a single optic often put surgeons in a dilemma, exchanging lenses early on the patient may miss the possibility to adapt to the implant in the eye; on the other hand, the surgeon’s decision to delay the surgery can make it all the more complex owing to capsular fibrosis. Tackling these predicaments, IVO’s Precisight® is time-independent and offers flexibility to both surgeon and patient. Essentially, Precisight® consists of a base and a front lens where the base lens functions as a docking station to host the front lens. Together, both lenses contribute the refractive power required by the eye for clear vision. Suppose the outcome of the surgery results in unclear vision for a patient over a period of time, only the easily accessible front lens is required to be exchanged or modified. The lens can be implanted without changing the workflow in the operation theatre, certainly an economic advantage for both patient and surgeon, all while minimizing the risk associated with a full lens explantation. More importantly, the post-cataract surgery can be performed in about five minutes, an advantage that currently no other solution renders in the market.
What gives the IVO’s premium IOL an economic advantage is the lens can be implanted without changing the workflow in the operation theatre
“What differentiates Precisight® IOL is the built-in intelligence that anticipates the potential need to enhance the patients’ vision or to change the optical technology in the eye,” says Carsten Laue, President, IVO. If the patient and the surgeon decide to improve the vision, the exchange lens is calculated by using IVO’s online enhancement calculator, which can also be used to order the new optic directly at the manufacturer. The surgeon can further optimize it by merely entering the patient’s anatomical data (anterior chamber depth as well as anterior and posterior keratometry). Once the data is fed into the calculator, it determines the best vision-enhancing lens for chosen target refraction.
Citing a recently published research report, Laue highlights that every four out of ten patients with modified corneas (e.g. following a LASIK procedure some 10 or 20 years ago) have manifest refraction resulting in larger than 0.5 diopters post-cataract surgery, hence a presumably suboptimal vision. This makes patients spectacle-dependent despite them having invested in a premium product potentially capable to result in spectacle-free vision. With IVO’s Precisight® patients can avoid the frustration and disappointment of poor vision and achieve an optimal vision that is free of spectacles, thereby, improving quality of life.
The ISO 13485-certified IVO has achieved CE mark of its products and is currently operating out of France and Germany with plans to foray into international markets. With a continuous focus on innovation, IVO will soon introduce new optical features such as toric and multifocal lenses to the platform. “We also intend to become the reference product in terms of quality of vision after cataract treatment or refractive lens exchange optics to better understand patient’s preferences in conjunction with his or her anatomical precondition. The idea is to deliver personalized solutions that will lead to implants tailored for individual patient,” concludes Laue.